Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune Encephalitis Diagnostics and Neurodevelopmental Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Caspr2/CNTNAP2 drug discovery and diagnostic development. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CNTNAP2 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled (<1 EU/μg). Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CNTNAP2 Products |
| Gene Delivery | CNTNAP2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for Cell-Based Assays (CBA). |
View CNTNAP2 Products |
| Benchmark Ab | Anti-CNTNAP2 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View CNTNAP2 Products |
| Validator | CNTNAP2 siRNA Set For target knockdown and specificity verification in neuronal cultures. |
View CNTNAP2 Products |
| Related Target A | LGI1 Leucine-rich glioma-inactivated 1. Co-implicated with Caspr2 in autoimmune limbic encephalitis; essential for differential panels. |
View LGI1 Products |
| Related Target B | Contactin-2 / CNTN2 Transient obligate binding partner of Caspr2 at the juxtaparanodes; critical for disruption assays. |
View CNTN2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Autoantibody Binding | HEK293 host expression ensures native post-translational modifications and complex folding of the large extracellular domain. |
| Stable Cell Line Construction for CBA | High-titer Lentivirus particles bypass transient transfection variability in clinical diagnostic assay setups. |
| Lack of Controls | Sequence-verified Clinical Benchmark Antibodies (Biosimilars) included as assay calibrators. |
| False Positives in Patient Serum | Validated siRNA and homolog panel (CNTNAP family) available for rigorous specificity screening. |
Live Caspr2/CNTNAP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic and diagnostic race for Caspr2 (Contactin-associated protein-like 2, encoded by the CNTNAP2 gene) is expanding beyond traditional neurology. Historically recognized as a major autoantigen in limbic encephalitis, Morvan syndrome, and neuromyotonia, Caspr2 is now a pivotal target for neurodevelopmental disorder research, including autism spectrum disorders (ASD) and refractory epilepsy.
As the clinical need for highly specific diagnostic differentiation grows, the R&D pipeline is shifting focus from basic autoantibody detection to advanced antigen-specific immunotherapies. Emerging therapeutic strategies aim to selectively deplete or neutralize anti-Caspr2 pathogenic autoantibodies without inducing broad systemic immunosuppression, utilizing decoy receptors, antigen-specific immunoadsorption, and engineered cell therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| In Vitro Diagnostics (IVD) | Euroimmun, Grifols, Laboratory Corp | Autoimmune Encephalitis, Neuromyotonia | Conformational Antigen Integrity (Need HEK293-expressed ECD-Fc) |
| Antigen-Specific Immunotherapy | Academic Medical Centers, Biotech Startups | Limbic Encephalitis, Morvan Syndrome | Decoy Binding Assays (Need high-purity monomeric and dimeric Caspr2 proteins) |
| Gene Therapy / Small Molecule | Neuroscience-focused Biopharma | Autism (CNTNAP2 deficiency), Epilepsy | Stable Cell Line Expression (Need Lentivirus-mediated ORF delivery) |